251 results on '"Casali, P.G."'
Search Results
2. Outcome improvement with chemotherapy and radiotherapy in primary, localized, radiation-associated angiosarcoma of the breast region: a retrospective case series analysis
3. Epithelioid hemangioendothelioma, an ultra-rare cancer: a consensus paper from the community of experts
4. Final analysis of the randomized trial on imatinib as an adjuvant in localized gastrointestinal stromal tumors (GIST) from the EORTC Soft Tissue and Bone Sarcoma Group (STBSG), the Australasian Gastro-Intestinal Trials Group (AGITG), UNICANCER, French Sarcoma Group (FSG), Italian Sarcoma Group (ISG), and Spanish Group for Research on Sarcomas (GEIS)☆
5. Clinical prognostic factors in advanced epithelioid haemangioendothelioma: a retrospective case series analysis within the Italian Rare Cancers Network
6. Gastrointestinal stromal tumours: ESMO–EURACAN–GENTURIS Clinical Practice Guidelines for diagnosis, treatment and follow-up
7. The sacral chordoma margin
8. Bone sarcomas: ESMO–PaedCan–EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up
9. Soft tissue and visceral sarcomas: ESMO–EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up
10. Gastrointestinal stromal tumours: ESMO–EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up
11. Gastrointestinal stromal tumours
12. Best practices for the management of local-regional recurrent chordoma: a position paper by the Chordoma Global Consensus Group
13. Patient-derived solitary fibrous tumour xenografts predict high sensitivity to doxorubicin/dacarbazine combination confirmed in the clinic and highlight the potential effectiveness of trabectedin or eribulin against this tumour
14. Bone sarcomas: ESMO–EURACAN–GENTURIS–ERN PaedCan Clinical Practice Guideline for diagnosis, treatment and follow-up
15. Supplementary Figure 1 from Dacarbazine in Solitary Fibrous Tumor: A Case Series Analysis and Preclinical Evidence vis-à-vis Temozolomide and Antiangiogenics
16. Supplementary Figure 3 from Dacarbazine in Solitary Fibrous Tumor: A Case Series Analysis and Preclinical Evidence vis-à-vis Temozolomide and Antiangiogenics
17. Supplementary Figure 2 from Dacarbazine in Solitary Fibrous Tumor: A Case Series Analysis and Preclinical Evidence vis-à-vis Temozolomide and Antiangiogenics
18. 61P Pazopanib in the real-world setting: Data from the Italian national registry
19. Correlation between radiological assessment and histopathological diagnosis in retroperitoneal tumors: Analysis of 291 consecutive patients at a tertiary reference sarcoma center
20. Long-term follow-up of patients with GIST undergoing metastasectomy in the era of imatinib – Analysis of prognostic factors (EORTC-STBSG collaborative study)
21. Sporadic desmoid-type fibromatosis: a stepwise approach to a non-metastasising neoplasm—a position paper from the Italian and the French Sarcoma Group
22. The current and future role of the medical oncologist in the professional care for cancer patients: a position paper by the European Society for Medical Oncology (ESMO)
23. Soft tissue and visceral sarcomas
24. ‘Rare cancers’: not all together in clinical studies!
25. Sunitinib malate in solitary fibrous tumor (SFT)
26. Adjuvant therapy in primary GIST: state-of-the-art
27. Frontline extended surgery is associated with improved survival in retroperitoneal low- to intermediate-grade soft tissue sarcomas
28. Gastrointestinal stromal tumours: ESMO–EURACAN–GENTURIS Clinical Practice Guidelines for diagnosis, treatment and follow-up
29. Sunitinib in advanced alveolar soft part sarcoma: evidence of a direct antitumor effect
30. Primary extremity soft tissue sarcomas: outcome improvement over time at a single institution
31. Soft tissue sarcomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
32. Gastrointestinal stromal tumours: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
33. Post-imatinib surgery in advanced/metastatic GIST: is it worthwhile in all patients?
34. 1547P Trabectedin in soft-tissue sarcoma patients in Italy: Analysis of real-world data from a national registry
35. Response to imatinib plus sirolimus in advanced chordoma
36. Trabectedin in myxoid liposarcomas (MLS): a long-term analysis of a single-institution series
37. Ewing's sarcoma of the bone: ESMO Clinical Recommendations for diagnosis, treatment and follow-up
38. Osteosarcoma: ESMO Clinical Recommendations for diagnosis, treatment and follow-up
39. Soft tissue sarcomas: ESMO Clinical Recommendations for diagnosis, treatment and follow-up
40. Gastrointestinal stromal tumours: ESMO Clinical Recommendations for diagnosis, treatment and follow-up
41. Preoperative imatinib mesylate for unresectable or locally advanced primary gastrointestinal stromal tumors (GIST)
42. Soft tissue sarcomas: ESMO Clinical Recommendations for diagnosis, treatment and follow-up
43. Gastrointestinal stromal tumors: ESMO Clinical Recommendations for diagnosis, treatment and follow-up
44. Phase II, open-label study of PTK787/ZK222584 for the treatment of metastatic gastrointestinal stromal tumors resistant to imatinib mesylate
45. Data protection and research in the European Union: a major step forward, with a step back
46. Phase II study on lapatinib in advanced EGFR-positive chordoma†
47. 1625MO ABCB1/P-glycoprotein (Pgp) expression as stratification factor for treatment of patients with non metastatic extremity high grade osteosarcoma: An Italian Sarcoma Group (ISG) multicentric prospective trial (ISG/OS-2)
48. 604TiP ON-TRK: A non-interventional study of larotrectinib in patients with TRK fusion cancer
49. 1667TiP A phase II, single arm study of avelumab in combination with axitinib in patients with unresectable/metastatic gastrointestinal stromal tumor after failure of standard therapy - AXAGIST
50. Myoepithelial tumours of soft tissues and extraskeletal myxoid chondrosarcomas feature a distinct transcriptional pattern
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.